Healthcare report · Week 42 · Oct 12 – 16, 2026
Health care: who led, who lagged, what comes next
Why health care led the market in the week to Oct 16, the companies the trend screens flagged, the year's outliers and the reports ahead — closing prices, Fri Oct 9 to Fri Oct 16, 2026.
Summary
- Health care was the third-best of the 11 S&P 500 sectors in the week to Oct 16: the sector fund XLV gained 3.5% while the S&P 500 lost 2.0% and technology lost 7.7%, as investors swapped growth stocks for defensive ones.
- 47 of 54 large health-care companies rose; the typical one gained 4.0%. Insurers led (+5.5%), biotech companies lagged (+1.4%); the biggest gains were IDEXX Laboratories (+8.2%), CVS Health (+7.2%) and Medtronic (+7.1%).
- The trend screens point up on 11 health-care companies worth $10B or more and down on 2 (Bristol Myers Squibb and HCA Healthcare).
- Moderna is up 639% this year, the sector's standout, though it fell 3.1% this week; the insurers follow (typical company +21.9%), while Boston Scientific (−53%) and Insulet (−50%) are the year's weakest.
- The lead holds while XLV stays above its 50-day average ($170.00, 3.8% under Friday's $176.71); a close below it would say the rotation into health care has stalled — with Intuitive Surgical, Thermo Fisher, Abbott, Danaher and Elevance Health reporting in the coming week as the first test.
Why health care led this week
Over the week to Oct 16, investors moved money out of technology and into defensive sectors, and health care was the third-best of the 11 sectors.
Health care was the third-best of the 11 S&P 500 sectors in the week to Fri Oct 16: the sector fund XLV gained 3.5%, behind consumer staples (+5.0%) and energy (+4.9%). The S&P 500 fund (SPY) lost 2.0% and technology (XLK) lost 7.7%. Over the past month health care ranks second of the 11 (+5.3%).
Health-care companies sell medicines, devices and care that people need in good times and bad, so their profits depend less on the economy than a chip maker's. That is why investors reach for them when they sell growth stocks. XLV closed the week at $176.71, its highest close of the past year.
On Friday alone (1 day), the typical defensive blue-chip stock moved +0.80% while the typical large growth stock moved −4.64% — a gap of 5.44 percentage points in favour of the defensive stocks.
Interest rates eased a little. The 10-year Treasury yield stood at 5.10% at its latest reading (Oct 15), down 0.12 points from a week earlier, and long-dated Treasury bonds (TLT) gained 2.7% over the week. Lower yields help defensive sectors, whose steady profits are valued much like bond income.
If the broad market wins back this week's loss — the S&P 500 fund (SPY) closing above last Friday's $778.57 — investors would have less reason to hide in defensive stocks, and health care's lead would likely narrow.
The scoreboard
Of the 54 large health-care companies tracked here, 47 rose over the week to Oct 16; the typical one gained 4.0%.
47 of the 54 companies rose over the week and 7 fell; the typical one gained 4.0%. The biggest gains: IDEXX Laboratories (+8.2%), CVS Health (+7.2%) and Medtronic (+7.1%). The weakest: Humana (−4.3%), Insmed (−4.3%) and Moderna (−3.1%). By group, insurers did best (typical company +5.5%) and biotech companies least (+1.4%).
| Group | 1 week | 1 month | 3 months | Year to date |
|---|---|---|---|---|
| Insurers 6 companies | +5.5% | +5.2% | +4.4% | +21.9% |
| Hospitals, pharmacies & distributors 7 companies | +5.3% | +7.0% | +20.9% | +16.4% |
| Tools, labs & diagnostics 7 companies | +4.2% | +7.8% | +13.9% | +0.1% |
| Medical devices 12 companies | +4.1% | +2.0% | +4.5% | -8.7% |
| Drugmakers 12 companies | +3.6% | -0.6% | +1.7% | +10.0% |
| Biotech 10 companies | +1.4% | +1.8% | +16.8% | +15.9% |
| Fund | 1 week | 1 month | 3 months | Year to date |
|---|---|---|---|---|
| XLV Health care sector fund | +3.5% | +4.7% | +11.0% | +14.2% |
| IBB Biotech fund (largest companies weigh most) | -2.2% | -2.5% | +8.3% | +19.7% |
| XBI Biotech fund (equal weight) | -6.2% | -8.8% | -4.4% | +18.4% |
| IHI Medical-device fund | +3.9% | +4.0% | +6.2% | -13.5% |
| IHF Health-care providers fund | +3.3% | +3.7% | +3.9% | +22.3% |
| SPY S&P 500 fund | -2.0% | +0.1% | +2.9% | +11.9% |
| XLK Technology sector fund | -7.7% | -2.4% | +4.4% | +27.4% |
Among biotech, size mattered: the fund where the largest companies weigh most (IBB) lost 2.2%, while the equal-weight fund (XBI), where small drug developers count as much as the giants, lost 6.2%. Medical-device makers (IHI) gained 3.9% and health-care providers (IHF) gained 3.3%.
| Ticker | 1 week | 1 month | 3 months | Year to date |
|---|---|---|---|---|
| LLY Eli Lilly · Drugmakers | +6.6% | +9.1% | +9.6% | +17.0% |
| GSK GSK · Drugmakers | +6.5% | -3.0% | -1.1% | +1.0% |
| ZTS Zoetis · Drugmakers | +6.1% | +8.7% | +4.2% | -36.9% |
| NVS Novartis · Drugmakers | +4.8% | +6.9% | +0.7% | +9.2% |
| PFE Pfizer · Drugmakers | +4.6% | +7.0% | +19.5% | +18.8% |
| AZN AstraZeneca · Drugmakers | +3.9% | -0.4% | +0.5% | -10.0% |
| ABBV AbbVie · Drugmakers | +3.2% | +8.1% | +12.7% | +24.9% |
| SNY Sanofi · Drugmakers | +1.4% | -5.9% | -7.7% | -16.2% |
| BMY Bristol Myers Squibb · Drugmakers | +1.1% | -4.9% | -0.7% | +10.8% |
| NVO Novo Nordisk · Drugmakers | +0.5% | -10.1% | -21.7% | -23.7% |
| MRK Merck · Drugmakers | +0.2% | -0.8% | +17.3% | +38.7% |
| JNJ Johnson & Johnson · Drugmakers | -2.2% | -5.4% | +2.7% | +23.5% |
| REGN Regeneron · Biotech | +5.9% | +0.2% | +17.6% | +2.4% |
| AMGN Amgen · Biotech | +4.2% | +13.9% | +18.8% | +32.1% |
| ONC BeOne Medicines · Biotech | +4.1% | +4.4% | +18.8% | +21.5% |
| GILD Gilead Sciences · Biotech | +3.3% | +3.5% | +17.2% | +27.2% |
| BIIB Biogen · Biotech | +3.1% | +6.2% | +16.4% | +32.2% |
| ALNY Alnylam · Biotech | -0.4% | -5.6% | -15.0% | -41.7% |
| ARGX argenx · Biotech | -0.7% | -17.7% | -3.2% | -2.6% |
| VRTX Vertex · Biotech | -2.0% | -3.2% | +4.0% | +10.2% |
| MRNA Moderna · Biotech | -3.1% | +37.9% | +266.5% | +639.3% |
| INSM Insmed · Biotech | -4.3% | -22.4% | -10.0% | -44.7% |
| MDT Medtronic · Medical devices | +7.1% | +2.1% | +13.8% | -1.4% |
| ZBH Zimmer Biomet · Medical devices | +6.5% | +0.8% | +5.9% | +5.6% |
| SYK Stryker · Medical devices | +6.2% | +5.2% | -7.7% | -16.2% |
| ABT Abbott · Medical devices | +5.3% | +2.6% | +3.2% | -16.3% |
| BDX Becton Dickinson · Medical devices | +4.3% | +5.7% | +24.1% | +25.7% |
| PODD Insulet · Medical devices | +4.3% | -0.3% | -15.7% | -50.4% |
| BSX Boston Scientific · Medical devices | +3.9% | +1.9% | +1.4% | -53.5% |
| RMD ResMed · Medical devices | +3.9% | +4.6% | +20.3% | -0.8% |
| ALC Alcon · Medical devices | +3.2% | +1.5% | -5.5% | -16.0% |
| DXCM Dexcom · Medical devices | +2.3% | -2.1% | +13.7% | +29.6% |
| EW Edwards Lifesciences · Medical devices | +1.6% | -1.9% | +1.9% | +1.6% |
| ISRG Intuitive Surgical · Medical devices | +0.7% | +11.2% | +20.8% | -24.7% |
| IDXX IDEXX Laboratories · Tools, labs & diagnostics | +8.2% | +10.6% | -0.6% | -17.2% |
| GEHC GE HealthCare · Tools, labs & diagnostics | +5.8% | +8.0% | +10.7% | -15.2% |
| TMO Thermo Fisher · Tools, labs & diagnostics | +4.9% | +4.8% | +31.1% | +19.1% |
| DHR Danaher · Tools, labs & diagnostics | +4.2% | +7.8% | +13.9% | +0.1% |
| STE Steris · Tools, labs & diagnostics | +3.9% | +7.0% | +3.8% | -12.2% |
| IQV IQVIA · Tools, labs & diagnostics | +2.7% | -0.9% | +30.9% | +18.4% |
| A Agilent · Tools, labs & diagnostics | +1.4% | +10.6% | +32.8% | +27.1% |
| CI Cigna · Insurers | +7.0% | +9.5% | +6.5% | +9.8% |
| UNH UnitedHealth · Insurers | +5.8% | +7.0% | -4.8% | +21.6% |
| CNC Centene · Insurers | +5.8% | +3.1% | +5.0% | +68.1% |
| MOH Molina Healthcare · Insurers | +5.3% | +1.1% | -9.7% | +19.5% |
| ELV Elevance Health · Insurers | +3.8% | +3.4% | +12.0% | +22.2% |
| HUM Humana · Insurers | -4.3% | +7.5% | +3.8% | +61.3% |
| CVS CVS Health · Hospitals, pharmacies & distributors | +7.2% | +2.3% | -14.2% | +16.4% |
| MCK McKesson · Hospitals, pharmacies & distributors | +7.0% | +14.2% | +20.9% | +22.5% |
| CAH Cardinal Health · Hospitals, pharmacies & distributors | +6.9% | +12.2% | +12.5% | +23.6% |
| COR Cencora · Hospitals, pharmacies & distributors | +5.3% | +10.2% | +12.2% | +0.9% |
| UHS Universal Health Services · Hospitals, pharmacies & distributors | +4.4% | +2.4% | +22.9% | -15.1% |
| HCA HCA Healthcare · Hospitals, pharmacies & distributors | +1.7% | +7.0% | +23.9% | -1.7% |
| THC Tenet Healthcare · Hospitals, pharmacies & distributors | +1.3% | +2.0% | +37.5% | +34.5% |
The 54 companies: US-listed health-care companies worth roughly $10B or more, grouped by what they sell — European and other foreign drugmakers through their US-listed shares (ADRs, US-traded certificates for a foreign company's stock). The tobacco companies Altria and British American Tobacco, which the market's trend screens file under health care, are covered in the Consumer staples report instead; CVS Health, which the screens file under consumer staples, is here (pharmacies plus the insurer Aetna). Returns are from daily closing prices, not counting dividends.
Breadth is what made this week a rotation: 47 of 54 rose. If the gains narrow to a handful of large drugmakers and insurers while most of the group falls, money would be thinning out of the sector rather than spreading through it.
What the trending screens flagged
The trend screens point up on 11 health-care companies worth $10B or more this week and down on 2.
The market's trend screens look for stocks crossing their average-price lines, reaching momentum extremes or making unusually large moves. They check 656 US-listed companies worth $10B or more. In the five sessions to Oct 15, their signals point up on 11 health-care companies — Eli Lilly, AbbVie, UnitedHealth, Novartis, Abbott, Medtronic, McKesson, Stryker, IDEXX Laboratories, BeOne Medicines and Royalty Pharma — and down on 2: Bristol Myers Squibb and HCA Healthcare.
| Ticker | Company | Signals point | 1 week | What the screens saw |
|---|---|---|---|---|
| IDXX | IDEXX Laboratories | Up | +8.2% | closed back above its 150-day average; short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; closed back above its 9-day average; RSI 66, near the overbought line; moved +8.2% in a week |
| LLY | Eli Lilly | Up | +6.6% | closed back above its 50-day average; RSI 69, near the overbought line; an unusually large one-day gain for its size (+3.5%); moved +6.6% in a week |
| ONC | BeOne Medicines | Up | +4.1% | short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; closed back above its 9-day average; traded more than twice its usual daily volume |
| NVS | Novartis | Up | +4.8% | short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; closed right at its 150-day average |
| RPRX | Royalty Pharma plc | Up | +7.1% | short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; a 'shooting star' day: rallied, then gave the gain back to close near the low; closed back above its 9-day average; moved +7.1% in a week |
| SYK | Stryker | Up | +6.2% | short-term trend turned up (9-day average crossed above the 20-day); closed back above its 9-day average; moved +6.2% in a week |
| MDT | Medtronic | Up | +7.1% | short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average; moved +7.1% in a week |
| MCK | McKesson | Up | +7.0% | RSI rose above 70 (overbought); moved +7.0% in a week |
| UNH | UnitedHealth | Up | +5.8% | short-term trend turned up (9-day average crossed above the 20-day); closed back above its 50-day average |
| ABT | Abbott | Up | +5.3% | short-term trend turned up (9-day average crossed above the 20-day); closed back above its 9-day average |
| ABBV | AbbVie | Up | +3.2% | RSI rose above 70 (overbought); RSI turned down from overbought |
| BMY | Bristol Myers Squibb | Down | +1.1% | closed below its 150-day average; closed back above its 9-day average; a 'shooting star' day: rallied, then gave the gain back to close near the low; RSI turned up from oversold; RSI fell below 30 (oversold) |
| HCA | HCA Healthcare | Down | +1.7% | RSI turned down from overbought; RSI rose above 70 (overbought) |
Across all health-care companies worth $2B or more, 98 flashed at least one upward signal in those five sessions and 82 a downward one.
The screens also list British American Tobacco and Altria under health care; they are tobacco companies and appear in the Consumer staples report.
- 50-day / 150-day average
- The average closing price of the past 50 or 150 sessions — common gauges of the medium-term trend. Closing back above one is read as the trend turning up.
- 9-day and 20-day averages
- Short-term trend lines that weight recent days most; the 9-day crossing above the 20-day marks a short-term turn up.
- RSI
- The relative strength index (0–100) compares recent gains with recent losses; above 70 is usually read as overbought, below 30 as oversold.
- Candle patterns
- Shapes of a single day's trading range — e.g. a 'shooting star' rallies and then gives the gain back by the close.
Bristol Myers Squibb is the one large health-care name the screens point down on. It closed below its 150-day average ($60.16, 0.7% over Friday's close). A close back above that line would end the slide in its medium-term trend.
The year's outliers
Year to date, health care holds one of the market's biggest winners — Moderna, +639% — and some of its sharpest losers.
Moderna (MRNA) is the year's best performer here by far: +639% since Dec 31, so the shares are worth about 7.4 times what they were at the start of the year. Biotech built on mRNA, the technology behind its COVID-19 vaccine; it is developing cancer vaccines with Merck. The run gathered pace in August, when Moderna and Merck reported that their personalised cancer vaccine cut the return of melanoma in a late-stage trial, and again this month on news of a government push to speed up cancer vaccines and the stock's entry into the Nasdaq-100 (Moderna stock surges more than 600% in 2026 (Quartz); Moderna shares skyrocket on success of cancer drug trial (Forbes, Aug 19)). This week it lost 3.1%, including a 7.8% drop on Friday; it closed 40.7% above its 50-day average with an RSI of 62, and reports next on Nov 6.
The insurers are the year's other winners: the typical one is up 21.9% since Dec 31, led by Centene (+68.1%) and Humana (+61.3%). In April the US government set next year's payments to private Medicare plans far above its first proposal, which lifted the group (Schaeffer’s, Apr 7). This week the typical insurer gained 5.5%.
The laggards. At the other end, Boston Scientific (−53%), Insulet (−50%), Insmed (−45%), Alnylam (−42%) and Zoetis (−37%) are the weakest this year. Boston Scientific — Medical devices for the heart and blood vessels, including heart-rhythm treatment systems. Insulet — Tubeless insulin pumps (Omnipod). Insmed — Biotech: treatments for rare lung diseases. Even so, 8 of the 10 weakest rose this week — the rotation lifted most of the sector.
Moderna closed 40.7% above its 50-day average ($154.93). A close below that line would mean the year's biggest run in health care has broken its short-term trend.
Earnings: this week and ahead
UnitedHealth and Johnson & Johnson reported this week; the sector's next reports start on Oct 20, with 7 reports in the coming week.
UnitedHealth reported its July–September 2026 results on Oct 13 before the market opened: earnings per share (adjusted) of $4.69 beat the $4.12 analysts expected by 13.8%. The shares moved −0.2% that day and +5.8% over the week (company release).
Johnson & Johnson also reported this week and raised its full-year outlook, but a one-time charge for its proposed talc litigation settlement cut its reported profit (company release). Its results are not in the earnings data used here; its shares lost 2.2% on the week.
Mon Oct 190
Before market open
—
After market close
—
Tue Oct 201
Before market open
—
After market close
Wed Oct 215
Before market open
After market close
Thu Oct 221
Before market open
After market close
—
Fri Oct 230
Before market open
—
After market close
—
Companies reporting earnings, by day and time: US-listed, market value $10.0B or more — 7 reports in all. ±% is the share-price move options traders expect around the report, where options data is available; the bar compares it with the week's largest. Option-implied moves exist only for companies worth $100B or more.
The share-price move options traders expect around each report, against the average move after its past reports: Intuitive Surgical ±8.5% vs ±6.7% (larger than, 8 reports); Thermo Fisher ±5.2% vs ±5.1% (about in line with, 8 reports); Abbott ±4.8% vs ±5.9% (smaller than, 7 reports); Danaher ±6.0% vs ±5.1% (larger than, 8 reports).
| Date | Ticker | Company | Market value | Time | Move options expect | Avg move, past reports (n) |
|---|---|---|---|---|---|---|
| Tue Oct 27 | NVS | Novartis | $287B | Before open | ±3.3% | ±2.6% (4) |
| Tue Oct 27 | HCA | HCA Healthcare | $101B | Before open | ±5.6% | ±4.7% (8) |
| Tue Oct 27 | IQV | IQVIA | $44.6B | Before open | n/a | n/a |
| Tue Oct 27 | CNC | Centene | $34.8B | Before open | n/a | n/a |
| Tue Oct 27 | UHS | Universal Health Services | $11.0B | After close | n/a | n/a |
| Wed Oct 28 | GSK | GSK | $99.2B | Before open | n/a | n/a |
| Wed Oct 28 | BSX | Boston Scientific | $64.0B | Before open | n/a | n/a |
| Wed Oct 28 | BIIB | Biogen | $34.8B | Before open | n/a | n/a |
| Wed Oct 28 | GEHC | GE HealthCare | $31.8B | Before open | n/a | n/a |
| Thu Oct 29 | LLY | Eli Lilly | $1.18T | Before open | ±5.7% | ±8.0% (8) |
| Thu Oct 29 | MRK | Merck | $358B | Before open | ±5.8% | ±2.4% (8) |
| Thu Oct 29 | BMY | Bristol Myers Squibb | $124B | Before open | ±3.9% | ±4.3% (8) |
| Thu Oct 29 | ALNY | Alnylam | $31.3B | Before open | n/a | n/a |
| Thu Oct 29 | THC | Tenet Healthcare | $22.2B | Before open | n/a | n/a |
| Thu Oct 29 | INSM | Insmed | $21.7B | Before open | n/a | n/a |
| Thu Oct 29 | GILD | Gilead Sciences | $195B | After close | n/a | ±4.6% (8) |
| Thu Oct 29 | SYK | Stryker | $112B | After close | ±6.1% | ±3.5% (8) |
| Thu Oct 29 | RMD | ResMed | $34.1B | After close | n/a | n/a |
| Thu Oct 29 | DXCM | Dexcom | $33.1B | After close | n/a | n/a |
| Fri Oct 30 | ABBV | AbbVie | $501B | Before open | ±3.7% | ±3.5% (8) |
| Fri Oct 30 | SNY | Sanofi | $98.3B | Before open | n/a | n/a |
| Fri Oct 30 | REGN | Regeneron | $82.0B | Before open | n/a | n/a |
| Fri Oct 30 | AZN | AstraZeneca | $258B | After close | ±3.5% | ±2.4% (4) |
| Mon Nov 2 | IDXX | IDEXX Laboratories | $43.1B | Before open | n/a | n/a |
| Mon Nov 2 | VRTX | Vertex | $129B | After close | n/a | ±6.2% (8) |
| Tue Nov 3 | PFE | Pfizer | $168B | Before open | ±4.0% | ±2.2% (8) |
| Tue Nov 3 | AMGN | Amgen | $235B | After close | ±4.0% | ±4.9% (8) |
| Wed Nov 4 | NVO | Novo Nordisk | $174B | Before open | ±6.1% | ±3.6% (4) |
| Wed Nov 4 | CVS | CVS Health | $118B | Before open | ±5.7% | ±5.7% (8) |
| Wed Nov 4 | COR | Cencora | $65.2B | Before open | n/a | n/a |
| Wed Nov 4 | ZBH | Zimmer Biomet | $18.0B | Before open | n/a | n/a |
| Wed Nov 4 | MCK | McKesson | $116B | After close | ±5.4% | ±4.2% (8) |
| Wed Nov 4 | EW | Edwards Lifesciences | $50.8B | After close | n/a | n/a |
| Wed Nov 4 | STE | Steris | $21.9B | After close | n/a | n/a |
| Thu Nov 5 | CI | Cigna | $79.0B | Before open | n/a | n/a |
| Thu Nov 5 | CAH | Cardinal Health | $58.7B | Before open | n/a | n/a |
| Thu Nov 5 | BDX | Becton Dickinson | $52.8B | Before open | n/a | n/a |
| Thu Nov 5 | ONC | BeOne Medicines | $42.5B | Before open | n/a | n/a |
| Thu Nov 5 | ZTS | Zoetis | $32.4B | Before open | n/a | n/a |
| Fri Nov 6 | MRNA | Moderna | $94.4B | Before open | n/a | n/a |
| Fri Nov 6 | HUM | Humana | $51.9B | Before open | n/a | n/a |
Move options expect: the share-price move options traders price in around the report (companies worth $100B or more only). Average move: the average size of the share-price move the day after its reports over the past two years. “No extra move priced”: options price no more movement around the report than on an ordinary day — itself a finding.
If either of the first large reports of the coming week closes outside the range options price, measured from Friday's close, between Oct 21 and Oct 22 — Intuitive Surgical (reports Oct 20 after the close; ±8.5% → below $390.35 or above $463.05); Thermo Fisher (reports Oct 21 before the open; ±5.2% → below $654.33 or above $725.67) — results, not the rotation, would be setting the sector's direction.
How stretched the move is
After the week's gains, 37 of 54 large health-care companies trade above their 50-day average and 5 show overbought readings.
The RSI (relative strength index, 0–100) compares recent gains with recent losses; above 70 is usually read as overbought — a sign a run has gone far quickly — and below 30 as oversold. 5 of the 54 companies closed the week at 70 or above: McKesson (76), Cardinal Health (74), Cigna (73), AbbVie (71) and Cencora (70). 1 sits at 30 or below (Insmed). The sector fund XLV's RSI is 66.
37 of the 54 close above their 50-day average and 37 of 54 above their 200-day — the average closing price of the past 200 sessions, a common gauge of the long-term trend. XLV sits 4.0% above its 50-day and 12.2% above its 200-day. 3 companies closed within 1% of their highest close of the past year: Thermo Fisher, Gilead Sciences and Elevance Health.
| Ticker | Company | RSI | vs 50-day avg | vs 200-day avg | vs 52-week high |
|---|---|---|---|---|---|
| MRNA | Moderna | 62 | +40.7% | +181.7% | −7.8% |
| MCK | McKesson | 76 | +12.1% | +17.7% | +0.0% |
| ISRG | Intuitive Surgical | 65 | +8.9% | −2.9% | −28.0% |
| A | Agilent | 62 | +8.9% | +28.6% | −1.5% |
| ABBV | AbbVie | 71 | +8.8% | +22.0% | +0.0% |
| CAH | Cardinal Health | 74 | +8.4% | +15.6% | +0.0% |
| CI | Cigna | 73 | +8.4% | +7.8% | −2.2% |
| TMO | Thermo Fisher | 64 | +8.4% | +26.1% | −0.9% |
| HCA | HCA Healthcare | 63 | +7.6% | +3.1% | −15.8% |
| ZTS | Zoetis | 69 | +7.3% | −17.2% | −46.2% |
If the overbought readings cool while prices hold, the move is resting. If the count above the 50-day average (37 of 54 now) drops toward half, the selling would have spread across the sector rather than hitting a few stretched names.
Company deep dives
Eli Lilly, CVS Health, Bristol Myers Squibb and Abbott: the largest company, the week's best large one, the one the screens point down on and the first trending name to report.
Four companies, each picked by a rule rather than by taste: Eli Lilly — the largest health-care company by market value; CVS Health — the best week among those worth $100B or more; Bristol Myers Squibb — the largest company the trend screens point down on this week; Abbott — the first of the names the screens point up on to report results.
| Measure | Eli Lilly (LLY) | CVS Health (CVS) | Bristol Myers Squibb (BMY) | Abbott (ABT) |
|---|---|---|---|---|
| Close, Oct 16 | $1,257.03 | $92.36 | $59.75 | $104.89 |
| Market value | $1.18T | $118B | $124B | $181B |
| 1 week | +6.6% | +7.2% | +1.1% | +5.3% |
| Year to date | +17.0% | +16.4% | +10.8% | −16.3% |
| vs 50-day average | +6.5% | +0.7% | −5.9% | −0.9% |
| vs 200-day average | +16.4% | +4.7% | +0.2% | +2.0% |
| vs 52-week high | −1.8% | −16.5% | −12.2% | −19.7% |
| RSI | 69 | 58 | 44 | 59 |
| Forward P/E | 26.6 | 10.8 | 9.0 | 17.3 |
| PEG (1-year) | 0.77 | 1.77 | n/a | 1.75 |
| Next report | Oct 29 | Nov 4 | Oct 29 | Oct 21 |
| Move options expect | ±5.7% | ±5.7% | ±3.9% | ±4.8% |
| Level to watch below | $1,224.83 | $88.18 | none found | none found |
Forward P/E: share price ÷ analysts' expected earnings per share for the next financial year. PEG (1-year): forward P/E ÷ expected earnings growth over the next year only — n/a where growth is expected to be zero or negative, or for companies worth under $100B. Level to watch below: the closest price at least 2% under Friday's close where the stock turned at least twice in the past year (intraday trading), else its 50- or 200-day average — not a forecast that it will turn there.
Eli Lilly (LLY). Drugmaker; its obesity and diabetes medicines (tirzepatide, sold as Mounjaro and Zepbound) drive most of its growth. It gained 6.6% this week and is +17.0% this year, 1.8% below its highest close of the past year; it trades 6.5% above its 50-day average with an RSI of 69. It trades at 26.6 times next year's expected earnings (PEG ratio 0.77). It reports on Oct 29 before the open; options price a ±5.7% move against an average of ±8.0% after its past 8 reports.
A close below $1,224.83, the nearest price where the stock turned at least twice before (2.6% under Friday's close), would mean this week’s gain is unwinding rather than consolidating.
CVS Health (CVS). Pharmacy chain that also owns the health insurer Aetna and a pharmacy-benefit manager. It gained 7.2% this week and is +16.4% this year, 16.5% below its highest close of the past year; it trades 0.7% above its 50-day average with an RSI of 58. It trades at 10.8 times next year's expected earnings (PEG ratio 1.77). It reports on Nov 4 before the open; options price a ±5.7% move against an average of ±5.7% after its past 8 reports.
A close below $88.18, its 200-day average (4.5% under Friday's close), would mean this week’s gain is unwinding rather than consolidating.
Bristol Myers Squibb (BMY). Drugmaker: cancer, blood-thinner and immunology medicines. It gained 1.1% this week and is +10.8% this year, 12.2% below its highest close of the past year; it trades 5.9% below its 50-day average with an RSI of 44. It trades at 9.0 times next year's expected earnings. It reports on Oct 29 before the open; options price a ±3.9% move against an average of ±4.3% after its past 8 reports.
Its Oct 29 report: a close outside the ±3.9% range options price — below $57.41 or above $62.09, measured from Friday's close — on Oct 29 or Oct 30 would mean the results moved the stock more than traders were ready for.
Abbott (ABT). Medical devices, diagnostic tests, nutrition and generic drugs; its glucose monitors are a fast-growing line. It gained 5.3% this week and is −16.3% this year, 19.7% below its highest close of the past year; it trades 0.9% below its 50-day average with an RSI of 59. It trades at 17.3 times next year's expected earnings (PEG ratio 1.75). It reports on Oct 21 before the open; options price a ±4.8% move against an average of ±5.9% after its past 7 reports.
Its Oct 21 report: a close outside the ±4.8% range options price — below $99.86 or above $109.92, measured from Friday's close — on Oct 21 or Oct 22 would mean the results moved the stock more than traders were ready for.
Scenarios
Three ways the coming weeks could go for health-care stocks, each tied to a level in this week's data — conditions to watch, not forecasts.
The rotation keeps going
- If
- technology keeps falling and XLV holds above its 20-day average ($170.89)
- Then
- health care extends its lead, and the insurers and drugmakers that led this week stay in front
- Watch
- the coming week's reports (Intuitive Surgical, Thermo Fisher, Abbott, Danaher and Elevance Health) clearing the moves options price
Leadership pauses
- If
- XLV trades between its 50-day average ($170.00) and this week's highs
- Then
- the overbought readings (RSI 66 on the sector fund) cool off without a fall in price
- Watch
- how many names the trend screens still point up on next Friday
The trade unwinds
- If
- XLV closes below its 50-day average ($170.00), or the S&P 500 fund wins back last Friday's $778.57 as technology rebounds
- Then
- money flows back to growth stocks and this week's health-care gains fade
- Watch
- Bristol Myers Squibb and the other names the screens already point down on